Jodi Van Dyk
Biographic Data
| ID | 7447560 |
|---|---|
| NAME | Jodi Van Dyk |
| GIVEN NAMES | Jodi |
| FAMILY NAME | Van Dyk |
| SIGNATURE | VAN DYK J |
| AFFILIATIONS | UNSW Sydney |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons. The finding that reinfection accounts for most recurrent viremia could assist retreatment clinical decision-making in prison
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use
The relatively high incidence of reinfection seen in this study underscores the importance of targeted harm reduction measures and monitoring for HCV reinfections within the first year following successful treatment among people who inject drugs. Additional research into integrated models of care incorporating harm reduction and supporting reducing risk of reinfection and HCV treatment are needed
No prominent works on this page.
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use
The relatively high incidence of reinfection seen in this study underscores the importance of targeted harm reduction measures and monitoring for HCV reinfections within the first year following successful treatment among people who inject drugs. Additional research into integrated models of care incorporating harm reduction and supporting reducing risk of reinfection and HCV treatment are needed
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons. The finding that reinfection accounts for most recurrent viremia could assist retreatment clinical decision-making in prison
Antiviral therapy (2 works) · Drug (2 works) · Hepatitis B Virus Studies (2 works) · Hepatitis C (2 works) · Hepatitis C virus (2 works) · Hepatitis C virus research (2 works) · HIV, Drug Use, Sexual Risk (2 works) · Antiviral drug (1 work) · Chronic hepatitis (1 work) · Hepacivirus (1 work)